The imidazoline I 2 receptor is an emerging drug target for analgesics. This study extended previous studies by examining the antinociceptive effects of three I 2 receptor agonists (2-BFI, BU224, and CR4056) in the formalin test. The receptor mechanisms and anatomical mediation of I 2 receptor agonist-induced antinociception were also examined. Formalin-induced flinching responses (2%, 50 μl) were quantified after treatment with I 2 receptor agonists alone or in combination with the I 2 receptor antagonist idazoxan. Anatomical mediation was studied by locally administering 2-BFI into the plantar surface or into the right lateral ventricle through cannulae (intracerebroventricular). The locomotor activity was also examined after central (intracerebroventricular) administration of 2-BFI. 2-BFI (1-10 mg/kg, intraperitoneal) and BU224 (1-10 mg/kg, intraperitoneal) attenuated the spontaneous flinching response observed during 10 min (phase 1) and 20-60 min (phase 2) following formalin treatment, whereas CR4056 (1-32 mg/kg, intraperitoneal) decreased only phase 2 flinching response. The I 2 receptor antagonist idazoxan attenuated the antinociceptive effects of 2-BFI and BU224 during phase 1, but not phase 2. Peripheral administration of 2-BFI (1-10 mg/kg, intraplantar) to the hind paw of rats had no antinociceptive effect. In contrast, centrally delivered 2-BFI (10-100 µg, intracerebroventricular) dose-dependently attenuated phase 1 and phase 2 flinching at doses that did not reduce the locomotor activity. Together, these data revealed the differential antinociceptive effects of I 2 receptor agonists and the differential antagonism profiles by idazoxan, suggesting the involvement of different I 2 receptor subtypes in reducing different phases of formalin-induced pain-like behaviors. In addition, the results also suggest the central mediation of I 2 receptor agonist-induced antinociceptive actions.
Introduction
Chronic pain reduces the quality of life and imparts high health costs and economic loss to society. Unfortunately, currently available analgesics are not adequate to meet the clinical needs, leaving a large population with undertreated pain (Institute of Medicine, USA, 2011). Opioids and NSAIDs are the most widely used analgesics; however, their use is constrained by limited effectiveness to certain painful conditions and adverse side effects. Although the understanding of pain mechanisms has greatly improved over the past few decades, this has not translated into adequate new clinically effective analgesics (Mogil, 2009) . Thus, there is still a dire need for the development of novel pharmacotherapy to treat pain.
The imidazoline I 2 receptor is an emerging drug target for the development of analgesics as I 2 receptor agonists demonstrate antinociceptive effects in rodent models of acute and chronic pain (Ferrari et al., 2011; Li et al., 2011 Li et al., , 2014 Meregalli et al., 2012; Sampson et al., 2012) . For example, the I 2 receptor agonist CR4056 reduces mechanical hyperalgesia in rat models of complete Freund's adjuvant (CFA)-induced inflammatory pain and chemotherapy-induced painful neuropathy in animals (Ferrari et al., 2011; Meregalli et al., 2012) . We also found that I 2 receptor agonists reduce CFA-induced inflammatory pain and nerve-injury-induced neuropathic pain . The formalin test is one of the most commonly used pain assay. Introduced in 1977, this test allows for the study of nocifensive behaviors without restraint, and with a continuous source of stimulation (Dubuisson and Dennis, 1977) . After an injection of formalin into the skin of the rodent hind paw, an intense early phase (phase 1) of hind paw guarding, licking, and flinching behaviors emerges and subsides about 10 min after formalin injection, which is followed by reappearing nocifensive behaviors that last as long as 1 h (phase 2). Phase 1 of this test is thought to be a direct effect of formalin on nociceptive fibers (neurogenic pain), whereas phase 2 has long been ascribed to formalin-induced inflammation (inflammatory pain) (Hunskaar and Hole, 1987) . Thus, one assay can examine the antinociceptive effects of potential analgesics on two types of pain. However, the effects of I 2 receptor agonists on formalin pain are unknown. The purpose of the current study is two-fold. First, this study examined the antinociceptive effects of three I 2 receptor agonists [2-BFI (2-(2-benzofuranyl)-2-imidazoline)hydrochloride, BU224 (2-(4,5-dihydroimidazol-2-yl)quinolone) hydrochloride, and CR4056 (2-phenyl-6-(1H imidazol-1yl)quinazoline)], all of which reportedly have antihyperalgesic effects in animal models of inflammatory and neuropathic pain (Ferrari et al., 2011; Li et al., 2014) in the formalin test, to examine the generality of the antinociceptive actions of I 2 receptor agonists. Given the reported antinociceptive profiles of the three I 2 receptor agonists, it was expected that all would produce similar and dose-dependent antinociceptive effects in both phases of the formalin test. Because the antihyperalgesic effects of all the three I 2 receptor agonists were antagonized by the commonly used nonselective I 2 receptor antagonist idazoxan (Ferrari et al., 2011; Li et al., 2014) , it was also anticipated that idazoxan would be able to attenuate the antinociceptive effects of these same I 2 receptor agonists in the formalin test in the current study. Second, because little is known of the anatomical (i.e. central vs. peripheral) mediation of I 2 receptor agonistinduced antinociception, this study also examined whether I 2 receptor agonists are acting through a peripherally or centrally mediated mechanism to produce their antinociceptive effects.
Methods

Subjects
Adult male Sprague-Dawley rats (Harlan, Indianapolis, Indiana, USA) were housed individually on a 12/12-h light/dark cycle (behavioral experiments were conducted during the light period) with free access to water and food except during experimental sessions. Animals were maintained and experiments were conducted in accordance with guidelines of the International Association for the Study of Pain (Zimmermann, 1983) and were approved by the Institutional Animal Care and Use Committee, University at Buffalo, the State University of New York, and with the 2011 Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources on Life Sciences, National Research Council, National Academy of Sciences, Washington, DC).
Formalin test
Groups of 6-7 rats were assigned to each dose-drug combination and each rat was tested once. Formalin (2%, 50 μl) was injected using a 28-G needle into the dorsal surface of the right hind paw while the rat was restrained manually. Immediately after formalin injection, the rat was placed into the observation arena (acrylic clear chamber: 40 cm × 40 cm × 30 cm) and scoring was commenced. A mirror was placed behind the chamber and opposite to the experimenter to facilitate visual observation. Flinching is characterized as a rapid and brief withdrawal or flexion of the injected paw. This painrelated behavior was quantified by counting the number of flinches for 5-min period at 0-80 min following formalin administration. Two phases of spontaneous flinching behavior were observed: an initial acute phase (phase 1: during the first 10 min after the formalin injection) and a prolonged tonic phase (phase 2: beginning about 20 min after the formalin injection). For drug studies, formalin was injected 10 min following pretreatment with I 2 receptor agonists (intraperitoneally or subcutaneously), or immediately following intracerebroventricular administration. When drugs were studied in combination, the first drug was administered 10 min before the second drug, which was followed by formalin injection 10 min later. The pretreatment time was based on previous studies showing that this time was sufficient to achieve maximal behavioral effects (Qiu et al., , 2015 . For peripheral drug administration, the study drug was administered into the plantar surface skin of the right hind paw (intraplantar). The experienced observers were blind to drug treatments. For the drug combination studies, the doses of agonists that produced the maximal antinociceptive effects in the single acute dose studies were used and the doses of idazoxan were chosen according to previous studies, which showed significant blockade of antinociceptive effects induced by I 2 receptor agonists (Meregalli et al., 2012; Li et al., 2014) .
Stereotaxic surgery
Rats were anesthetized using ketamine/xylazine (60/5 mg/kg, intraperitoneal) and placed into a stereotaxic frame (Model #962; David Kopf Instruments, Tujunga, California, USA). Stainless steel guide cannulae (26 G; Plastics One, Roanoke, Virginia, USA) were inserted into the right lateral ventricle. The stereotaxic coordinates for intracranial cannulae were: A/P = − 0.9; M/L = + 1.4; D/V = − 1.8. Following implantation, guide cannulae were secured to the skull with cranioplastic cement and cranial screws, and stylets were placed into the guide cannulae to prevent blockage. Cannula placement was verified by administering 10 ng of angiotensin II in TBS using injector cannulae that extended 1.5 mm past the guide cannulae and observing drinking behavior for 30 min (Vento et al., 2012) .
Locomotor activity
Locomotor activity was monitored by an infrared motorsensor system (AccuScan Instruments, Columbus, Ohio, USA) fitted outside clear acrylic chambers (40 cm × 40 cm × 30 cm) that were cleaned between test sessions. Locomotor activity (distance traveled) was analyzed for 1 h immediately after intracerebroventricular drug administration with the Versa Max animal activity monitoring software (AccuScan Instruments) . Drugs 2-BFI, BU224, and CR4056 were synthesized according to standard procedures (Jarry et al., 1997; Ishihara and Togo, 2007) . Idazoxan hydrochloride was purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Unless otherwise noted, all drugs were dissolved in physiological saline and administered either intraperitoneally or intraplantarlly (peripheral), or dissolved in Dulbecco's Phosphate Buffered Saline and administered intracerebroventricularly (central). CR4056 was dissolved in 20% DMSO with saline and a drop of HCl and administered intraperitoneally. Doses are expressed as milligram of the form indicated earlier per kilogram body weight. Injection volumes were 1 ml/kg for intraperitoneal administration, 50 μl for intraplantar, and 4 μl for intracerebroventricular.
Data analyses
The total number of flinches observed during 10 min (phase 1) and 20-60 min (phase 2) following formalin treatment were collected and analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc analysis. P value less than 0.05 was considered statistically significant. The analysis of phase 2 included only the data between 20 and 60 min after formalin injection because it was found that data after 60 min tended to converge among groups and did not represent the drug effects.
Results
The flinching response is not a natural behavior and rats without formalin treatment did not display flinching (data not shown). Under control conditions, rats displayed flinching behavior in two distinct phases following injection of formalin to their hind paw ( Fig. 1 ). Formalin produced flinching immediately following injection, which lasted 10 min and corresponded to phase 1 (Fig. 1) . Phase 2 flinching occurred 20 min following formalin treatment and lasted 60 min (Fig. 1) . The total flinches observed during phase 1 (0-10 min) and phase 2 (20-60 min) following formalin were plotted as a function of pretreatment drug dose (Fig. 2 ). Both 2-BFI ( Fig. 2 ) and BU224 (Fig. 2 ) decreased flinching behavior in both phases. One-way ANOVA revealed a significant main effect of 2-BFI on phase 1 [F(3, 23) = 10.06, P < 0.001] and phase 2 [F(3, 23) = 6.09, P < 0.01] flinching. Post-hoc analyses indicated that the effects induced by 3.2 and 10 mg/kg 2-BFI were significantly different from that induced by vehicle control for both phases. Similarly, one-way ANOVA revealed that BU224 produced a significant main effect on phase 1 [F(3, 23) = 11.58, P < 0.001] and phase 2 [F(3, 23) = 17.77, P < 0.001] flinching. Post-hoc analyses indicated that the effects induced by 3.2 and 10 mg/kg BU224 were significantly different from control during phase 1, whereas effects induced by all doses of BU224 were significantly different from control during phase 2. In contrast, CR4056 failed to produce a significant effect on flinching behavior during phase 1 (Fig. 2) . One-way ANOVA revealed that CR4056 produced a significant effect in phase 2 [F(4, 29) = 4.68, P < 0.01]. Post-hoc analyses indicated Formalin-induced flinching in rats (n = 6 per group). Vertical axis, total flinches every 5 min; horizontal axis, time following formalin treatment (min). that the effect induced by 32 mg/kg CR4056 was significantly different from that of control group during phase 2 flinching (Fig. 2) .
To examine the pharmacological mechanism of the antinociceptive effects induced by I 2 receptor agonists, the commonly used imidazoline I 2 receptor antagonist idazoxan was studied in combination with all the I 2 receptor agonists. Idazoxan alone up to a dose of 10 mg/kg had no significant effect on formalin-induced flinching behavior (Fig. 3) . When studied as a pretreatment, idazoxan significantly attenuated the antinociceptive effects of 2-BFI [F(2, 16) = 6.39, P < 0.05] and BU224 [F(2, 17) = 8.99, P < 0.01] during phase 1. Post-hoc analyses indicated that 10 mg/kg idazoxan significantly prevented the antinociceptive effects of 2-BFI and BU224. However, idazoxan failed to alter the antinociceptive effects of 2-BFI or BU224 during phase 2. Furthermore, although CR4056 produced antinociceptive effects only during phase 2 flinching, 3.2 mg/kg idazoxan failed to attenuate this effect. The larger dose of idazoxan (10 mg/kg) was studied as a pretreatment in one rat receiving 32 mg/kg CR4056 to examine whether the effect of CR4056 could be antagonized. A marked sedation was observed in this rat which likely precluded the expression of flinching behavior. Thus, testing with this dose combination was discontinued.
Intraplantar administration of 2-BFI to the rats' hind paw failed to produce antinociceptive effects (Fig. 4) . In contrast, one-way ANOVA revealed that central 2-BFI administration, by delivering the drug to the right lateral ventricle, produced a significant effect on the flinching behavior during phase 1 [F(3, 23) = 15.55, P < 0.001] and phase 2 [F(3, 23) = 23.07, P < 0.001]. Post-hoc analyses indicated that 32 and 100 µg 2-BFI produced significant effects compared with those of control group during phase 1, whereas all doses of 2-BFI produced effects that were significantly different from those of the control group during phase 2 (Fig. 4) . Furthermore, centrally administered 2-BFI failed to affect the rats' general locomotor activity (Fig. 5 ).
Discussion
The primary finding of the current study was that selective imidazoline I 2 receptor agonists produced antinociceptive effects in the formalin test, a well-validated rat model of tonic persistent pain. In addition, these effects appear to be acting through a centrally, but not peripherally, mediated mechanism. Interestingly, the data also showed that idazoxan-sensitive I 2 receptors primarily participate in the antinociceptive effects during phase 1 but not phase 2 of formalin test. Taken together, these data extend the previous findings that I 2 receptor agonists are effective against acute and chronic pain (Ferrari et al., 2011; Li et al., 2011 Li et al., , 2014 Meregalli et al., 2012) by showing that these ligands produce antinociception through a central mechanism.
The formalin test is a well-validated procedure and differs from most models of pain in two ways. First, most traditional tests of nociception are based on a phasic stimulus of high intensity and as the pain experience is short lasting, it is thus not possible to assess modulatory mechanisms that may be triggered by the stimulus itself (Tjolsen et al., 1992) . Second, formalin induces two distinct phases of nociceptive behavior consisting of an early phase (phase 1), which is predominantly caused by direct chemical stimulation of nociceptors, and a late phase (phase 2) due to an inflammatory reaction (Hunskaar and Hole, 1987) . As a result, the formalin test has been suggested to provide a more valid model for clinical pain compared with the traditional tests using a high-intensity phasic stimulus (Dubuisson and Dennis, 1977; Abbott et al., 1981) . Consistent with the literature, we found that formalin produced spontaneous flinching behavior when injected into the hind paw of rats and this occurred in two phases (Fig. 1) . The I 2 receptor agonists 2-BFI and BU224 attenuated flinching behavior during phase 1 and phase 2 following formalin treatment, whereas CR4056 Effects of peripheral (i.pl.) or central (i.c.v.) administration of 2-BFI on formalin-induced flinching (n = 6 per group). Vertical axis, total flinches during 0-10 min (phase 1, a) and 20-60 min (phase 2, b) following formalin treatment; horizontal axis, drug dose (mg/kg or µg). *P < 0.05 as compared with vehicle control. i.c.v., intracerebroventricular; i.pl., intraplantar
Antinociceptive effects of I 2 agonists Thorn et al. 381 decreased only phase 2 flinching (Fig. 2) . 2-BFI has previously been shown to produce antinociceptive effects in animal models of both nerve-injury-induced neuropathic pain and CFA-induced inflammatory pain .
In the formalin test, phase 1 is thought to be neurogenic and phase 2 is more related to inflammatory pain (Hunskaar and Hole, 1987) . The finding that both 2-BFI and BU224 produced antinociceptive effects for both phases extends previous findings by suggesting that such compounds are efficacious against both neuropathic and inflammatory pain.
Two unexpected findings need to be discussed. First, it was surprising that CR4056 attenuated the flinching behavior only during phase 2 but showed no significant effect during phase 1. In studies that evaluate the antinociceptive effects of CR4056 in models of CFA-induced inflammatory pain and capsaicin-induced mechanical hyperalgesia, the effects of CR4056 were completely blocked by the I 2 receptor antagonist idazoxan (Ferrari et al., 2011) . Idazoxan also attenuates the antinociceptive effects of 2-BFI in a rat model of CFA-induced pain . Using the drug discrimination assay, a procedure that is widely used to assess and compare the interoceptive effects induced by centrally active compounds, we found that both 2-BFI and CR4056 fully substitute for BU224 in rats discriminating 5.6 mg/kg BU224, which suggests that all the three compounds share similar pharmacological mechanisms (Qiu et al., 2015) . In addition, 2-BFI, BU224, and CR4056 all produce I 2 receptor-mediated hypothermia in rats (Thorn et al., 2012) . Besides the functional studies, receptor binding results also indicate that all the three compounds are highly selective I 2 receptor ligands and have little affinity for dozens of other receptors (Ferrari et al., 2011; Thorn et al., 2012) . All these results strongly suggest that CR4056 shares similar pharmacological mechanisms with 2-BFI and BU224 and should be expected to produce similar antinociceptive effects in formalin test. The lack of effect of CR4056 on phase 1 is not likely due to inadequate dosing or inadequate pretreatment time because both 2-BFI and BU224 show similar potencies in both phases, the doses of CR4056 studied are well within the dose range that produce many other behavioral effects including antinociception (Ferrari et al., 2011; Thorn et al., 2012; Qiu et al., 2014) , and the pretreatment time was sufficient to achieve maximal behavioral effects . Despite these similarities between CR4056 and other I 2 receptor agonists, emerging evidence suggests that important differences exist. In rats discriminating 10 mg/kg CR4056, 2-BFI only partially substitutes for CR4056, whereas BU224 neither substitutes for nor blocks the discriminative stimulus effects of CR4056 . The asymmetrical substitution between CR4056 and BU224 suggests that the two compounds have critical differences despite the apparent partially overlapping pharmacological effects. Thus, the different effects between BU224 and CR4056 on phase 1 of formalin test may be due to the nonoverlapping idazoxan-sensitive I 2 receptor subtypes, although the exact mechanism remains to be determined.
Another unexpected finding was that idazoxan was ineffective in blocking the antinociceptive effects of all the three I 2 receptor agonists on phase 2 of the formalin test. As discussed above, it should be expected that idazoxan should be able to attenuate the antinociceptive effects of the I 2 receptor agonists, as shown in other studies using different models of pain (Ferrari et al., 2011; Li et al., 2011 Li et al., , 2014 . Although idazoxan blocks some behavioral effects (notably antinociceptive effects) of I 2 receptor agonists, it produces similar discriminative stimulus effects with I 2 receptor agonists (Jordan et al., 1996; Qiu et al., 2014 Qiu et al., , 2015 and does not affect the behavioral effects of I 2 receptor agonists under certain conditions (Min et al., 2013) . These apparent discrepancies are interpreted as differential binding and/or functional activities of idazoxan and other I 2 receptor agonists on different I 2 receptor subtypes (Qiu et al., , 2015 . I 2 receptors are usually identified by [ 3 H]-2-BFI or [ 3 H]-idazoxan radioligands, and such binding sites are heterogeneous and consist of multiple proteins (Regunathan and Reis, 1996; Escriba et al., 1999) , including one that was recently identified as brain creatine kinase (Kimura et al., 2009) . It is likely that these different I 2 receptor subtypes are functionally different and that I 2 receptor ligands with differential binding activities on these subtypes have different functional effects . In the formalin test, the two phases differentially respond to some analgesics (Ossipov et al., 2000) . Thus, the discrepancy that idazoxan blocked the antinociceptive effects of I 2 receptor agonists only on phase 1 but not phase 2 might be due to the differential involvement of I 2 receptor subtypes in the modulation of formalin pain. It is plausible that 2-BFI and BU224 may exert antinociceptive effects on phase 1 through idazoxan-sensitive subtypes and attenuate the nociceptive behavior during phase 2 through idazoxaninsensitive subtypes of I 2 receptors. The lack of antagonism by idazoxan was not due to the low dose used, as much lower doses have been shown to block I 2 receptormediated effects (Thorn et al., 2012; Li et al., 2014) . The effects of I 2 receptor agonists in the formalin test are behaviorally specific because the doses of the compounds studied do not impair general behavior in rats (Thorn et al., 2012) .
I 2 receptors are expressed in most tissues and organs that have been studied (Regunathan and Reis, 1996) . Almost all studies using selective I 2 receptor ligands treat animals systemically. In one study, I 2 receptor agonists were found to enhance morphine antinociception when both were administered intracerebroventricularly, suggesting that the interaction occurs in the brain (Sanchez-Blazquez et al., 2000) . However, it is largely unclear whether the antinociceptive effects produced by I 2 receptor agonists are centrally or peripherally mediated. When 2-BFI was delivered directly to the hind paw before formalin treatment, no antinociception was observed (Fig. 4) . In contrast, centrally administered 2-BFI into the right lateral ventricle produced significant antinociception during both phases of the formalin test at doses that had no significant effect on the general locomotor behavior of rats (Fig. 5) . These results clearly showed that the antinociception of I 2 receptor agonists in formalin test is a centrally mediated event.
In summary, this study found that imidazoline I 2 receptor agonists produce antinociceptive effects in the formalin test through both idazoxan-sensitive and idazoxaninsensitive mechanisms. The observations of differential modulation of formalin pain by I 2 receptor agonists and differential antagonism by idazoxan suggest that there are functional differences between I 2 receptor subtypes. In addition, the selective I 2 receptor agonist 2-BFI produces antinociception through a central, but not peripheral mechanism. Taken together, this study further supports the notion that I 2 receptors represent a novel centrally active drug target to treat pain.
